Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-Dose Fasting In Vivo Bioequivalence Study of Oxybutynin Chloride Extended-release Tablets (5 mg; Mylan) and Ditropan XL® Tablets (5 mg; ALZA) in Healthy Volunteers

NCT00650481 is registered in ClinicalTrials.gov with Mylan Pharmaceuticals Inc as lead sponsor.

NCT NCT00650481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00650481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-Dose Fasting In Vivo Bioequivalence Study of Oxybutynin Chloride Extended-release Tablets (5 mg; Mylan) and Ditropan XL® Tablets (5 mg; ALZA) in Healthy Volunteers
Lead sponsor
Mylan Pharmaceuticals Inc
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2002
Completion date
January 31, 2003
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy